Company news

Xeris Biopharma Holdings, Inc. news in 2022

Xeris Biopharma Holdings, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Xeris Biopharma Announces Plans for a Phase II Dose-Finding Study for Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) as Replacement Therapy for Hypothyroidism

December 14, 2022

Xeris Biopharma Announces Research Collaboration and Option Agreement With Horizon Therapeutics plc for XeriJect™ Formulation of Teprotumumab

November 22, 2022

Xeris Biopharma Reports Third Quarter 2022 Financial Results and Recent Events

November 8, 2022

Xeris Biopharma to Report Third Quarter 2022 Financial Results on November 9, 2022

November 1, 2022

Xeris Biopharma Announces Results of the Extended Evaluation of Recorlev® (Levoketoconazole) From the Phase 3 Sonics Study Published in the European Journal of Endocrinology

October 31, 2022

Xeris Biopharma Announces Positive Topline Phase 1 Clinical Data of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121); Hosts Conference Call and Webcast

October 19, 2022

Xeris Biopharma Reports Second Quarter Financial Results and Upcoming Events

August 9, 2022

Xeris Biopharma to Report Second Quarter 2022 Financial Results on August 10, 2022

August 2, 2022

Xeris’ Commercialization Partner for Ogluo®, Tetris Pharma Ltd, to Be Acquired by Arecor Therapeutics

July 31, 2022

Xeris Announces Full Results From the Logics Study of Recorlev® and Presentation of New Burden of Illness in Cushing’s Syndrome Data at AACE Annual Meeting May 12-14

May 11, 2022

Xeris Biopharma Reports First Quarter Financial Results and Upcoming Events

May 10, 2022

Xeris Biopharma to Report First Quarter 2022 Financial Results on May 11, 2022

May 3, 2022

Xeris Biopharma Announces Gvoke® Kit Is Now Available for the Treatment of Severe Hypoglycemia in Adults and Children With Diabetes Ages 2 And Above

March 15, 2022

Xeris Biopharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Events

March 9, 2022

Xeris Announces $150M Senior Secured Term Loan Facility With Hayfin Capital

March 9, 2022

Xeris Biopharma to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

March 3, 2022

Xeris Biopharma to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

February 8, 2022

Xeris Biopharma Announces Recorlev® (levoketoconazole) Is Now Commercially Available for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome

January 30, 2022

Xeris Biopharma Reaffirms 2021 Guidance and Provides Business Update

January 17, 2022

Xeris Biopharma to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference

January 5, 2022

Xeris Biopharma Enters Into Agreement for $30 Million Private Placement

January 2, 2022

Calls in 2022

Decks in 2022